Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bertrand, M. E.
Right arrow Articles by Van Belle, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bertrand, M. E.
Right arrow Articles by Van Belle, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Triple antiplatelet treatment in patients presenting with non-ST-segment elevation acute coronary syndromes

Michel E. Bertrand* and Eric Van Belle

Lille Heart Institute, Hôpital Cardiologique, Boulevard du Professeur Leclercq, 59037 Lille, France

* Corresponding author. E-mail address: mbcardio{at}club-internet.fr

Antiplatelet drugs are pivotal in the management of non-ST-segment elevation acute coronary syndrome (ACSs). The guidelines recommend dual antiplatelet treatment associating aspirin and clopidogrel as a first-line treatment. In high-risk patients (with recurrent ischaemia, ST-segment depression, elevated troponins, and diabetics, according to the European Society of Cardiology guidelines) and moderate-to-high-risk patients (as assessed by the TIMI risk score in the ACC/AHA guidelines), it is recommended to add a glycoprotein IIb/IIIa receptor inhibitor to the baseline treatment, i.e. triple antiplatelet treatment. However, this latter strategy has not, until recently, been validated by proper, adequate randomized trials. This article considers the rationale and the evidence for triple antiplatelet treatment in high-risk patients presenting with non-ST-segment elevation ACSs.

Key Words: Aspirin • Clopidogrel • GpIIb/IIIa receptor blocker • Acute coronary syndromes • Platelet inhibition


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.